Related Experiment Videos
[A clinical study of prostatic carcinoma]
H Hashimoto1, M Sasaki, H Osanai
1Department of Urology, Asahikawa Medical College.
Hinyokika Kiyo. Acta Urologica Japonica
|February 1, 1989
Summary
For advanced prostate cancer (stage D), early combination therapy of hormonal agents and chemotherapy shows improved prognosis. However, initial treatments for poorly differentiated prostate cancer in stages A2, B, and C require enhancement.
Area of Science:
- Oncology
- Urology
Context:
- Retrospective analysis of 77 prostate carcinoma patients treated between 1977 and 1986.
- Initial treatments primarily involved hormonal agents.
Purpose:
- To evaluate treatment outcomes for different stages of prostate carcinoma.
- To identify potential improvements in therapeutic strategies, particularly for poorly differentiated cancers.
Summary:
- Stage A1 prostate cancer showed no relapse. Stage A2 cases had a high relapse rate to metastatic disease, with limited response to chemotherapy.
- Stage B patients generally had good outcomes, except for one with poorly differentiated carcinoma.
- Stage C patients, especially those with poorly differentiated tumors, exhibited hormone resistance, with limited success from radiotherapy and chemotherapy.
- Stage D patients receiving early combination hormonal therapy and chemotherapy demonstrated a better prognosis, even with poorly differentiated tumors and multiple bone metastases.
Impact:
- Suggests a need for improved initial therapy for poorly differentiated prostate cancer in stages A2, B, and C.
- Highlights the potential benefit of early combination chemotherapy for stage D prostate cancer patients with poor prognostic factors.